Autolus Earnings Reports

In Q2 2025, Autolus reported $20.9 million in product revenue from AUCATZYL’s U.S. launch and secured market coverage for over 90% of medical lives. Although R&D expenses declined, SG&A costs rose due to commercial scale-up. The company remains well-capitalized with $454.3 million in cash and marketable securities.

Autolus Therapeutics reported Q1 2025 net product revenue of $9.0 million for AUCATZYL, driven by strong physician enthusiasm and increasing patient access. The company also secured conditional marketing authorization for AUCATZYL in the UK and reported encouraging preliminary data from the Phase 1 CARLYSLE trial for systemic lupus erythematosus, with plans to advance into pivotal Phase 2 trials.

Autolus posted a Q4 net loss of $27.6 million with $29,000 in revenue and an EPS of -0.09. The quarter reflected ongoing investments into commercialization and pipeline development ahead of broader regulatory milestones.

Autolus Therapeutics reported a net loss of $82.1 million for the third quarter ended September 30, 2024. The FDA approved AUCATZYL, triggering a $30 million milestone payment from Blackstone. The company's cash and cash equivalents totaled $657.1 million.

Autolus Therapeutics reported a net loss of $58.3 million for the second quarter of 2024, compared to a net loss of $45.6 million for the same period in 2023. Cash and cash equivalents totaled $705.9 million as of June 30, 2024. The company is focused on commercial readiness activities for obecabtagene autoleucel (obe-cel).

Autolus Therapeutics reported a net loss of $52.7 million for Q1 2024, compared to a net loss of $39.8 million for the same period in 2023. Cash and cash equivalents totaled $758.5 million as of March 31, 2024, compared to $239.6 million as of December 31, 2023. The company is advancing its obe-cel program and other pipeline developments, supported by recent financing and strategic collaborations.

Autolus Therapeutics reported a net loss of $208.4 million for the year ended December 31, 2023, with cash and cash equivalents totaling $239.6 million. The company highlighted its strategic alliance with BioNTech and the submission of the BLA for obecabtagene autoleucel (obe-cel) to the FDA.